• Pharos Ibio applied to South Korea's Ministry of Food and Drug Safety on Nov. 12, 2026, to amend PHI-501's Phase 1 trial.
• The study evaluates safety, tolerability and preliminary activity in patients with advanced solid tumors carrying BRAF, KRAS or NRAS mutations.
• Pharmacokinetic findings from dose-escalation patients prompted proposed dosing adjustments for subsequent cohorts.
• Enrollment targets are up to 63 patients in dose escalation and 40 in dose optimization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharos Ibio Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261112900958), on November 12, 2026, and is solely responsible for the information contained therein.